HIV-associated lipodystrophy
| HIV-associated lipodystrophy | |
|---|---|
| Other names | Lipodystrophy in HIV-infected patients (LD-HIV) |
| Specialty | Immunology, dermatology, infectious diseases, endocrinology  |
HIV-associated lipodystrophy is a condition characterized by loss of
: 497Presentation
HIV-associated lipodystrophy commonly presents with fat loss in face, buttocks, arms and legs.[citation needed]
There is also fat accumulation in various body parts. Patients often present with "buffalo hump"-like fat deposits in their upper backs. Breast size of patients (both male and female) tends to increase. In addition, patients develop abdominal obesity.[citation needed]
Cause
The exact mechanism of HIV-associated lipodystrophy is not fully elucidated. There is evidence indicating both that it can be caused by anti-retroviral medications and that it can be caused by HIV infection in the absence of anti-retroviral medication.[citation needed]
Evidence implicating anti-retroviral medications
On the one hand, lipodystrophy seems to be mainly due to HIV-1
Evidence implicating HIV infection alone
On the other hand, there is evidence that
Management
GHRH analogs such as tesamorelin can be used to treat HIV-associated lipodystrophy.[citation needed]
Prognosis
Reversion of lipodystrophy does not occur after withdrawal of protease inhibitors.[2]
See also
- Drug-induced lipodystrophy
- Lipodystrophy
- List of cutaneous conditions
References
- ISBN 978-0-7216-2921-6.
- ^ S2CID 33325225.
- S2CID 28195183.
External links
| Authority control databases: National |
|---|